stocktools
Offerings // Kairos Pharma, LTD.

KAPA offering history

Every offering-related filing in Kairos Pharma, LTD.’s recent SEC record — registrations (announced capacity) kept separate from pricing documents (executed sales). Reviewed 120 filings back to Mar 29, 2023.

Last executed offering
Jan 17, 2025
8-K — priced deal (shares or notes)
Last registration (announced)
Jan 13, 2026
S-3 — capacity, not a sale
Executed, last 12 months
0
424B pricings + 8-K 3.02 sales
Registered, last 12 months
1
S-1/S-3/F-series registrations
DateFilingWhat it means
Apr 1, 2026424B3 →UPDATEProspectus update — often a resale registration, not necessarily new capital
Apr 1, 2026424B3 →UPDATEProspectus update — often a resale registration, not necessarily new capital
Jan 23, 2026EFFECT →EFFECTIVESEC declared a registration effective — selling can begin
Jan 13, 2026S-3 →REGISTEREDS-3 registration — capacity to sell shares, not a sale yet
Aug 19, 2025424B3 →UPDATEProspectus update — often a resale registration, not necessarily new capital
Apr 25, 2025424B3 →UPDATEProspectus update — often a resale registration, not necessarily new capital
Apr 24, 2025EFFECT →EFFECTIVESEC declared a registration effective — selling can begin
Apr 22, 2025S-1 →REGISTEREDS-1 registration — capacity to sell shares, not a sale yet
Feb 5, 2025424B3 →UPDATEProspectus update — often a resale registration, not necessarily new capital
Feb 4, 2025EFFECT →EFFECTIVESEC declared a registration effective — selling can begin
Jan 29, 2025S-1 →REGISTEREDS-1 registration — capacity to sell shares, not a sale yet
Jan 17, 20258-K →EXECUTEDUnregistered share sale disclosed (8-K item 3.02)
Jan 14, 20258-K →EXECUTEDUnregistered share sale disclosed (8-K item 3.02)
Sep 17, 2024424B4 →EXECUTEDFinal prospectus — offering priced (typical for IPOs and marketed share deals)
Sep 16, 2024EFFECT →EFFECTIVESEC declared a registration effective — selling can begin
Aug 16, 2024S-1/A →REGISTEREDS-1/A registration — capacity to sell shares, not a sale yet
Jun 4, 2024S-1/A →REGISTEREDS-1/A registration — capacity to sell shares, not a sale yet
May 24, 2024S-1/A →REGISTEREDS-1/A registration — capacity to sell shares, not a sale yet
May 20, 2024S-1/A →REGISTEREDS-1/A registration — capacity to sell shares, not a sale yet
May 13, 2024S-1/A →REGISTEREDS-1/A registration — capacity to sell shares, not a sale yet
May 1, 2024S-1/A →REGISTEREDS-1/A registration — capacity to sell shares, not a sale yet
Feb 14, 2024S-1/A →REGISTEREDS-1/A registration — capacity to sell shares, not a sale yet
Dec 7, 2023S-1/A →REGISTEREDS-1/A registration — capacity to sell shares, not a sale yet
Sep 29, 2023S-1 →REGISTEREDS-1 registration — capacity to sell shares, not a sale yet
KAPA offering-related filings from SEC EDGAR, newest first (capped at 40). Each links to the original document.

Two honest limits. (1) A 424B takedown can price shares or notes— EDGAR’s metadata doesn’t say which, so open the document: large investment-grade filers use these mostly for bond deals (no dilution), small-caps mostly for shares. (2) At-the-market (ATM) programs sell shares gradually and individual sales are not separately filed — the visible footprint is the enabling shelf and its 424B5; actual ATM share counts surface later in the 10-Q/10-K share count. Educational information from public filings, not investment advice.

Is a shelf active now? →Do they need money? →Red flags →Full KAPA workspace →
KAPA offering FAQ

When did KAPA last execute an offering?

Per SEC filings, Kairos Pharma, LTD.'s most recent priced offering document is a 8-K filed 2025-01-17. Note a 424B takedown can price shares or notes (debt) — the linked document says which.

When did KAPA last announce or register an offering?

The most recent registration is a S-3 filed 2026-01-13. A registration is capacity to sell shares — not a sale.

Does an offering always mean dilution?

Registered direct offerings and shelf takedowns issue new shares and dilute existing holders. Resale registrations (424B3/B7) let existing holders sell and do not create new shares. Secondary sales by insiders also do not dilute. Each row here is labeled with what it is.